Blueprint Medicines (BPMC) said Monday it now projects the peak revenue opportunity for its systemic mastocytosis franchise at $4 billion, with Ayvakit likely to achieve annual revenue of $2 billion by 2030.
The company said its BLU-808 treatment for mast cell disorders was well-tolerated at all doses tested in a phase 1 trial in healthy volunteers.
"The results show that BLU-808 performed consistently, with dose-dependent outcomes, including rapid, robust and sustained reductions in serum tryptase across a range of doses, which reinforce the potential for tunable treatment," Blueprint Medicines Chief Scientific Officer Percy Carter said in a press release Sunday.
The company continues to expect product revenue from Ayvakit between $475 million and $480 million for full-year 2024.
Blueprint Medicines shares were up nearly 10% in recent trading.
Price: 95.82, Change: +8.39, Percent Change: +9.60
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。